Viking Therapeutics Inc (NASDAQ:VKTX) shares traded 2.61% higher at $34.94 on Wall Street last session.
VKTX stock price is now -24.14% away from the 50-day moving average and -40.13% away from the 200-day moving average. The market capitalization of the company currently stands at $3.89B.
On November 22, 2024, B. Riley Securities recently initiated its ‘Buy’ rating on the stock quoting a target price of $109, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, Lian Brian, President & CEO sold 194,490 shares of the company’s stock on Jan 06 ’25. The stock was sold for $8,313,601 at an average price of $42.75. Upon completion of the transaction, the President & CEO now directly owns 2,366,570 shares in the company, valued at $82.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 06 ’25, Chief Operating Officer Mancini Marianna sold 54,215 shares of the business’s stock. A total of $2,317,599 was realized by selling the stock at an average price of $42.75. This leaves the insider owning 374,134 shares of the company worth $13.07 million. A total of 3.11% of the company’s stock is owned by insiders.
During the past 12 months, Viking Therapeutics Inc has had a low of $20.92 and a high of $99.41. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 36.47, and a quick ratio of 36.47. The fifty day moving average price for VKTX is $46.7344 and a two-hundred day moving average price translates $58.5638 for the stock.
The latest earnings results from Viking Therapeutics Inc (NASDAQ: VKTX) was released for 2024-09-30.
